Ulinastatin protects against cisplatin-induced ovarian damage via Nrf2/Keap1 pathway.

ABSTRACT: The administration of chemotherapeutic agents such as cisplatin frequently results in ovarian damage and premature ovarian failure (POF), severely compromising fertility and quality of life in young women. This study aimed to investigate the protective effects of ulinastatin, a compound with anti-inflammatory and antioxidant properties, against cisplatin-induced ovarian injury and to elucidate the underlying mechanisms through the Nrf2/Keap1 pathway. In vivo and in vitro models were established using cisplatin-treated rats and ovarian granulosa cells. Experimental results demonstrated that ulinastatin significantly alleviated cisplatin-induced ovarian structural damage, reduced follicular atresia, and inhibited ovarian fibrosis and inflammation. Furthermore, ulinastatin restored serum horm

SUBMITTER: Zhao L 

PROVIDER: S-EPMC12482159 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature